U.S., Aug. 12 -- ClinicalTrials.gov registry received information related to the study (NCT07758608) titled 'Renal Impairment Pharmacokinetics (PK) Trial of Afabicin' on Aug. 06.
Brief Summary: The primary purpose of this study is to assess the effect of renal impairment on the PK of afabicin desphosphono after a single oral 80 milligrams (mg) or intravenous (IV) 55 mg dose of afabicin.
Study Start Date: Aug., 2026
Study Type: INTERVENTIONAL
Condition:
Renal Impairment
Intervention:
DRUG: Afabicin Oral
Tablet
DRUG: Afabicin IV
IV infusion
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Debiopharm International SA
Published by HT Digital Content Services with permission from Health Daily Digest....